William Blair Investment Management Reduces $50M in IDEXX Laboratories, Inc. ($IDXX)

William Blair Investment Management has reduced its stake in IDXX by 89,703 shares, according to its latest 13F filing with the SEC. As of the reporting period, the firm holds 351,621 shares valued at approximately $196.1 million. This move represents a 20.3% decrease from its previous position of 441,324 shares.

What Changed in William Blair's IDXX Position

William Blair Investment Management trimmed its holdings in IDXX by 89,703 shares, bringing its total to 351,621 shares. The reduction reflects a 20.3% decrease, with the value of the remaining shares estimated at $196.1 million. This adjustment indicates a strategic repositioning of their investment in the company.

Other Institutional Activity in IDXX

Several other institutional investors also adjusted their positions in IDXX. BlackRock, Inc. reduced its stake by 169,333 shares, ending with 8,365,553 shares valued at about $4.7 billion. Meanwhile, Vanguard Capital Management LLC and Vanguard Portfolio Management LLC both maintained their positions, holding 5,182,507 and 3,910,863 shares, respectively. State Street Corp increased its holdings slightly by 17,559 shares to a total of 3,674,185 shares worth $2.1 billion. Geode Capital Management, LLC added 77,060 shares, bringing its total to 2,660,999 shares.

IDEXX Laboratories, Inc. Stock Up 0.5%

Shares of IDXX traded at $557.67. The company's market capitalization stands at approximately $196.1 million. The stock has been fluctuating with a 52-week range that investors are keeping a close eye on.

Insider Buying and Selling at IDEXX Laboratories, Inc.

On June 1, 2026, George Fennell, Executive Vice President, was active in trading IDXX shares. He purchased 639 shares and sold 284 shares on the same day. Sophie Vandebroek, Lawrence Kingsley, and Karen Peacock also bought 525 shares each on May 12, 2026.

Analysts Set New Price Targets

Analyst activity around IDXX has been notable. On April 28, 2026, UBS maintained a 'hold' rating with a price target of $640. Citigroup initiated coverage with a 'hold' rating and a $650 target on April 15. Stifel maintained a 'buy' rating with a $675 price target on March 31. Other analysts, including those from Barclays and Piper Sandler, have also issued ratings and targets, reflecting varied perspectives on the stock's future.

About IDXX

IDXX operates in the healthcare sector, providing diagnostic and information technology-based products and services. The company is headquartered in the United States and serves a global market, focusing on delivering innovative solutions to enhance animal health and food safety.

Bottom Line

William Blair's decision to reduce its IDXX holdings by 20% is a noteworthy shift, reflecting a change in its investment strategy. Investors often track such filings to gauge institutional sentiment. Remember, 13F filings are backward-looking and may not represent current holdings.